In the long game of medicine and fungi, antibacterial drugs were the endless “magic shield” that made them fall and saved lives. However, today’s silent and gruesome “drug-resistant crisis” is sweeping the globe, giving way to the old “savings of life.” Once again, human health is faced with serious challenges as a result of the erosion, and there is an urgent need for a deeper analysis of the causes, an understanding of the current situation and a search for solutions.
The causes are a multiplicity of factors, a combination of “generative” resistance. The abuse of antibacterial drugs is the first to be felt, and in the medical field, some doctors are held hostage to the patient’s eagerness or lack of precision in their diagnosis, overstretched the wide spectrum of antibacterial drugs, “big net fishing” which expose bacteria to the “life and death test”, and the unexploded strain of antibacterial bacteria, which thrives on the basis of limited equipment, and the use of empirical drugs and overdoses in primary health-care institutions is common. In livestock, in order to promote animal growth and prevent disease, farmers add a large number of antibacterials to feed, and in animals resistant bacteria pass through the food chain and end up at the human table and into the human body.
The bacteria themselves are also the main cause of this. They can “share” resistant genes between the same species or species of bacteria through mutations of genes, random changes in genetic codes, and mutations that in part give them resistance, such as “seventy-two” to drug “attacks; even worse, they use “level gene transfer” to “share” resistant genes between the same species or between different bacteria, so that resistance characteristics, such as wildfires, spread rapidly in the bacterial community and form resistance “group forces”.
The public’s misperceptions are “promoting”. Many mistook antibacterial drugs as “one-size-fits-all drugs”, as well as viruses such as flu and flu, to know that antibacterial drugs are “unable” to the virus, and that the use of futility is a deterrent to bacterial resistance. There’s an arbitrary drop-out, a non-compliance with the treatment, a slow interruption of the treatment, a “re-emergence” of the residual disease and greater resistance.
The state of affairs is a matter of concern, and the drug-resistant “glow cloud” is a global problem. Today, the drug-resistant fungus “family” is growing in magnitude, with the methooxin-resistant septococcus (MRSA) infesting the hospital with wounds, pulmonary infections, “drylists”, the carbon-acne-resistant intestinal bacteria (CRE) now in the intensive care unit, with “immunization” of most of the powerful antibacterial drugs, and the high mortality rate of multi-drug-resistant tuberculosis, which brings back the “cold winter” to tuberculosis control, with a long and limited course of treatment, with patients suffering from severe stress, with millions of deaths each year caused by drug-resistant infections, while the development of new antibacterials is struggling to form a “yellow” trap, and the treatment of infectious diseases is at risk.
Geographical disparities highlight the dilemmas, the strains of medical resources, gaps in regulation, high levels of anti-bacterial abuse in developing countries, and the prevalence of drug-resistant “high-risk areas”; and the high levels of international travel, trade and cross-border spread of drug-resistant bacteria in developed countries, with the global village becoming “Drug-resistant Gardens” with no room for self-reliance.
There’s a way to break it, and there’s a lot of work going on. Enhanced regulation is a “strength” and the health sector needs to scrutinize the prescription of anti-bacterial drugs to regulate the use of both medical and breeding channels, such as the European Union’s ban on the use of antibiotics for growth, which is modeled for all countries; and to improve diagnostic accuracy, using rapid pathogen testing, drug-sensitive testing, “targeted” by doctors, and to prevent the blind use of generic drugs.
Scientific “innovation engines” need to work, with increased government and business input, the excavation of new antibacterial targets, the development of new “weapons” such as cactus therapy, antibacterial platinum, etc., to break traditional drug limitations; and the global collaboration of academic institutions to share drug-resistant data and joint offensives to accelerate output.
Cope, “Springs and Rains,” positive. Through community lectures, new media science, the generalization of antibacterials, the public being made aware of the applicable conditions, the strict observance of the therapeutic process, the abandonment of erroneous habits, the reduction of unnecessary use of drugs from their source, and a concerted effort to build a firm line of defence and to disperse the antibacterials, the hazes, the re-picking of antibacterials, and the preservation of life and health, the oasis.
